The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells
As there are no effective treatments for advanced prostate cancer, exploring new therapies is crucial. BI6727(Volasertib), a PLK1 inhibitor, shows great promise as an anti-cancer drug. However, despite advancing to phase II and III trials in other cancers, BI6727 has shown limited anti-tumor activit...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-07-01
|
| סדרה: | Frontiers in Cell and Developmental Biology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fcell.2025.1602693/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|